...
bysi-img

BeyondSpring Inc, Common Stock

BYSI

NAQ

$1.75

+$0.16

(10.06%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$68.91M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
20.01K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.30
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.78 L
$4 H
$1.75

About BeyondSpring Inc, Common Stock

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBYSISectorS&P500
1-Week Return9%-0.94%-2.6%
1-Month Return-1.13%-5.08%-1.08%
3-Month Return-15.87%-10.62%3.45%
6-Month Return-29.58%-6.18%8.57%
1-Year Return92.52%1.98%24.3%
3-Year Return-64.43%-0.93%25.58%
5-Year Return-88.77%33.84%84.07%
10-Year Return-89.58%102.52%185.12%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-180.00K1.35M1.35M1.75M[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":10.28,"profit":true},{"date":"2021-12-31","value":77.16,"profit":true},{"date":"2022-12-31","value":77.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Cost of Revenue77.00K77.00K---[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Gross Profit(77.00K)103.00K1.35M1.35M1.75M[{"date":"2019-12-31","value":-4.4,"profit":false},{"date":"2020-12-31","value":5.88,"profit":true},{"date":"2021-12-31","value":77.16,"profit":true},{"date":"2022-12-31","value":77.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Margin(Infinity%)57.22%100.00%100.00%100.00%[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":57.22,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses40.31M64.39M67.59M38.59M24.86M[{"date":"2019-12-31","value":59.63,"profit":true},{"date":"2020-12-31","value":95.27,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":57.09,"profit":true},{"date":"2023-12-31","value":36.79,"profit":true}]
Operating Income(40.31M)(64.21M)(66.24M)(37.24M)(23.11M)[{"date":"2019-12-31","value":-4030700000,"profit":false},{"date":"2020-12-31","value":-6421100000,"profit":false},{"date":"2021-12-31","value":-6624000000,"profit":false},{"date":"2022-12-31","value":-3723900000,"profit":false},{"date":"2023-12-31","value":-2311400000,"profit":false}]
Total Non-Operating Income/Expense(48.00K)421.00K1.61M1.30M1.69M[{"date":"2019-12-31","value":-2.84,"profit":false},{"date":"2020-12-31","value":24.87,"profit":true},{"date":"2021-12-31","value":95.27,"profit":true},{"date":"2022-12-31","value":76.79,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(40.33M)(63.82M)(64.64M)(36.12M)(21.84M)[{"date":"2019-12-31","value":-4033300000,"profit":false},{"date":"2020-12-31","value":-6382100000,"profit":false},{"date":"2021-12-31","value":-6463800000,"profit":false},{"date":"2022-12-31","value":-3611700000,"profit":false},{"date":"2023-12-31","value":-2184200000,"profit":false}]
Income Taxes(2.04M)(2.76M)3.57M163.00K106.00K[{"date":"2019-12-31","value":-57.2,"profit":false},{"date":"2020-12-31","value":-77.28,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.57,"profit":true},{"date":"2023-12-31","value":2.97,"profit":true}]
Income After Taxes(38.29M)(61.06M)(68.21M)(36.28M)(21.95M)[{"date":"2019-12-31","value":-3829100000,"profit":false},{"date":"2020-12-31","value":-6106200000,"profit":false},{"date":"2021-12-31","value":-6820800000,"profit":false},{"date":"2022-12-31","value":-3628000000,"profit":false},{"date":"2023-12-31","value":-2194800000,"profit":false}]
Income From Continuous Operations(40.33M)(63.82M)(68.21M)(36.28M)(21.95M)[{"date":"2019-12-31","value":-4033300000,"profit":false},{"date":"2020-12-31","value":-6382100000,"profit":false},{"date":"2021-12-31","value":-6820800000,"profit":false},{"date":"2022-12-31","value":-3628000000,"profit":false},{"date":"2023-12-31","value":-2194800000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(38.29M)(61.06M)(68.21M)(36.28M)(21.03M)[{"date":"2019-12-31","value":-3829100000,"profit":false},{"date":"2020-12-31","value":-6106200000,"profit":false},{"date":"2021-12-31","value":-6820800000,"profit":false},{"date":"2022-12-31","value":-3628000000,"profit":false},{"date":"2023-12-31","value":-2102600000,"profit":false}]
EPS (Diluted)(3.54)(1.98)(1.72)--[{"date":"2019-12-31","value":-354,"profit":false},{"date":"2020-12-31","value":-198,"profit":false},{"date":"2021-12-31","value":-172,"profit":false},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BYSI
Cash Ratio 1.75
Current Ratio 1.82

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BYSI
ROA (LTM) -39.64%
ROE (LTM) -310.48%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BYSI
Debt Ratio Lower is generally better. Negative is bad. 2.26
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -1.44

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BYSI
Trailing PE NM
Forward PE 10.54
P/S (TTM) 37.59
P/B 5.38
EV/R 31.90
EV/Ebitda 0.05
PEG NM

FAQs

What is BeyondSpring Inc share price today?

BeyondSpring Inc (BYSI) share price today is $1.75

Can Indians buy BeyondSpring Inc shares?

Yes, Indians can buy shares of BeyondSpring Inc (BYSI) on Vested. To buy BeyondSpring Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BYSI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BeyondSpring Inc be purchased?

Yes, you can purchase fractional shares of BeyondSpring Inc (BYSI) via the Vested app. You can start investing in BeyondSpring Inc (BYSI) with a minimum investment of $1.

How to invest in BeyondSpring Inc shares from India?

You can invest in shares of BeyondSpring Inc (BYSI) via Vested in three simple steps:

  • Click on Sign Up or Invest in BYSI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BeyondSpring Inc shares
What is BeyondSpring Inc 52-week high and low stock price?

The 52-week high price of BeyondSpring Inc (BYSI) is $4. The 52-week low price of BeyondSpring Inc (BYSI) is $0.78.

What is BeyondSpring Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of BeyondSpring Inc (BYSI) is

What is BeyondSpring Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BeyondSpring Inc (BYSI) is 5.38

What is BeyondSpring Inc dividend yield?

The dividend yield of BeyondSpring Inc (BYSI) is 0.00%

What is the Market Cap of BeyondSpring Inc?

The market capitalization of BeyondSpring Inc (BYSI) is $68.91M

What is BeyondSpring Inc’s stock symbol?

The stock symbol (or ticker) of BeyondSpring Inc is BYSI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top